An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

被引:88
作者
Jehn, U
Bartl, R
Dietzfelbinger, H
Haferlach, T
Heinemann, V
机构
[1] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-81377 Munich, Germany
[2] Tech Univ, Munich, Germany
关键词
HCL; 2-CdA; long-term follow-up; retreatment with 2-CdA;
D O I
10.1038/sj.leu.2403418
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Long-term results of both pretreated and previously untreated patients (pts) with hairy cell leukemia (HCL) using uniformly a single 7-day course of 2-chlorodeoxyadenosine (2-CdA) by continuous infusion are reported. In addition, the probability of obtaining another response with this drug in pts who relapsed after 2-CdA treatment will be addressed. A total of 44 consecutive pts (34 males, 10 females) with a median age of 57 years (range 33-77) at the time of initiation of 2-CdA treatment were analyzed. In all, 11 pts were pretreated with either splenectomy (n = 6), interferon alpha (n = 9) or deoxycoformycin (dCF) (n = 3) or all procedures in sequence. Two pts treated with dCF did not respond to dCF, but only 2-CdA. The median time to the start of 2-CdA treatment of the 11 pretreated pts was 47 months (mo) (10-160). Out of 44, 43 (98%) achieved complete response (CR) (13 pts with residual disease-RD), one pt reached a good partial response with a single cycle of 2-CdA. Out of 44 pts, 13 had no nonhematologic toxicities at all. Toxicities (WHO grade I-IV) were mainly of grade I and II, in one pt grade IV infectious complication. Bone marrow biopsies were performed at the time of recovery of hematopoiesis, thereafter at 2-3 mo intervals, thereafter at 6 mo, and finally annually in 35 pts. The median follow-up is 8.5 years (0.1-12.2). Disease-free survival from the start of 2-CdA treatment is 36% at 12 years (median 8.4 years), 17/44 pts relapsed. Nine of these pts were treated with 2-CdA again, eight achieved a second CR (median 2.5 yrs), one pt did not respond. Eight of our cohort had a second malignancy before receiving 2-CdA. Six pts died in CR due to the second malignancy. The overall survival at 12 years after the start of 2-CdA treatment is 79%. 2-CdA is a safe and effective treatment of HCL inducing complete remissions in the majority of pts with only a single cycle of 2-CdA, and a paucity of toxicities. Responses are durable and long-lasting. Pts who relapsed following treatment with 2-CdA.
引用
收藏
页码:1476 / 1481
页数:6
相关论文
共 26 条
[1]   BONE-MARROW HISTOLOGY IN HAIRY-CELL LEUKEMIA - IDENTIFICATION OF SUBTYPES AND THEIR PROGNOSTIC-SIGNIFICANCE [J].
BARTL, R ;
FRISCH, B ;
HILL, W ;
BURKHARDT, R ;
SOMMERFELD, W ;
SUND, M .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1983, 79 (05) :531-545
[2]   LEUKEMIC RETICULOENDOTHELIOSIS [J].
BOURONCLE, BA ;
WISEMAN, BK ;
DOAN, CA .
BLOOD, 1958, 13 (07) :609-630
[3]  
BURNS GF, 1978, BLOOD, V52, P1132
[4]   ANTILEUKEMIC AND IMMUNOSUPPRESSIVE ACTIVITY OF 2-CHLORO-2'-DEOXYADENOSINE [J].
CARSON, DA ;
WASSON, DB ;
BEUTLER, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (07) :2232-2236
[5]   Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias [J].
Cheson, BD ;
Vena, DA ;
Barrett, J ;
Freidlin, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2454-2460
[6]  
ESTEY EH, 1992, BLOOD, V79, P882
[7]   Risk of second cancer in patients with Hairy Cell Leukemia:: Long-term follow-up [J].
Federico, M ;
Zinzani, PL ;
Frassoldati, A ;
Vinceti, M ;
Modè, A ;
Annino, L ;
Chisesi, T ;
Pagnucco, G ;
Invernizzi, R ;
Spriano, M ;
Resegotti, L ;
Bendandi, M ;
Damasio, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :638-646
[8]   HAIRY CELL LEUKEMIA - CLINICAL REVIEW BASED ON 71 CASES [J].
GOLOMB, HM ;
CATOVSKY, D ;
GOLDE, DW .
ANNALS OF INTERNAL MEDICINE, 1978, 89 (05) :677-683
[9]  
HAKIMIAN D, 1993, BLOOD, V82, P1798
[10]   RESPONSE TO PENTOSTATIN IN HAIRY-CELL LEUKEMIA REFRACTORY TO INTERFERON-ALPHA [J].
HO, AD ;
THALER, J ;
MANDELLI, F ;
LAURIA, F ;
ZITTOUN, R ;
WILLEMZE, R ;
MCVIE, G ;
MARMONT, AM ;
PRUMMER, O ;
STRYCKMANS, P ;
WITT, B ;
SUCIU, S ;
SOLBU, G ;
DEWITTE, T ;
BODEWADTRADZUN, S .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) :1533-1538